EMA Application withdrawn: Dexamethasone Taw (Dexamethasone (sodium phosphate)) — Taw Pharma (Ireland) Ltd

View source ↗

Summary

EMA withdrew the application for Dexamethasone Taw (dexamethasone sodium phosphate) by Taw Pharma (Ireland) Ltd.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arthritis
• Asthma
• Autoimmune Diseases
• Brain Edema
• Eye Diseases
• Inflammation
• Postoperative Nausea and Vomiting
• Respiratory Distress Syndrome Adult
• Skin Diseases
• Vomiting

Drugs mentioned

• Dexamethasone Taw (dexamethasone)

Snippet

Status: Application withdrawn. Therapeutic area: COVID-19 virus infection;Brain Edema;Respiratory Distress Syndrome, Adult;Asthma;Skin Diseases;Autoimmune Diseases;Arthritis;Vomiting;Inflammation;Eye Diseases;Postoperative Nausea and Vomiting. MAH: Taw Pharma (Ireland) Ltd